Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;29(3):161-6.
doi: 10.2337/diaspect.29.3.161.

The Future of Biosimilar Insulins

Anne Park Kim  1 , Ross Jason Bindler  1
Affiliations

The Future of Biosimilar Insulins

Anne Park Kim et al. Diabetes Spectr. 2016 Aug.

Abstract

IN BRIEF Biosimilar insulins are available in many countries and will be made available in the United States in the near future. Some concerns associated with biosimilar insulins include potential differences in the efficacy and safety between a biosimilar product and its reference insulin, the ramifications of having the same name or different names for a biosimilar and its reference insulin, the prospects of and limitations to substituting insulin products, and the proper implementation of pharmacovigilance. Still, health care providers will have the opportunity, with continued appropriate monitoring, to offer alternative, and possibly more individualized, therapy for diabetes management with the introduction of biosimilar insulins.

PubMed Disclaimer

References

    1. Rosenfeld L. Insulin: discovery and controversy. Clin Chem 2002;48:2270–2288 - PubMed
    1. Blackstone EA, Fuhr JP. The economics of biosimilars. Am Health Drug Benefits 2013;6:469–478 - PMC - PubMed
    1. Meek T. Sanofi sues Lilly over insulin patents. Available from http://www.pmlive.com/pharma_news/sanofi_sues_lilly_over_insulin_patents.... Accessed 18 April 2016
    1. Abasaglar [package insert]. Vienna, Austria, Eli Lilly Regional Operations GmbH, 2014. In Annex 1: Summary of Product Characteristics. Available from www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information.... Accessed 29 February 2016
    1. Clinical Trials.gov. A study of LY2963016 in healthy participants. Updated 3 October 2014. Available from https://clinicaltrials.gov/ct2/show/study/NCT01634165. Accessed 29 February 2016